

"Lung Experts Asia Pacific (LEAP) Symposia" NSCLC Treatment Landscape Bringing Evidence into Clinical Practice



Program Director : Dr. (Col) Ranga Rao Rangaraju

Time	Торіс	Faculty
7.30 - 7.35 pm	Welcome	Dr. (Col) Ranga Rao Rangaraju
7.35 - 7.45 pm	Updates on TKI in Lung Cancer	Dr Nitesh Rohatgi
7.45 - 7.55 pm	Roche Oncology Pipeline in Lung Cancer	Dr. Agnes C. I. Kiu Weber
7.55 - 8.40 pm	Angiogenesis Inhibition : Key to Improving Outcomes	Prof.Dr. Filippo de Marinis
8.40 - 9.10 pm	Panel Discussion : Role of Antiangiogenic Therapy in NSCLC	Dr Shyam Aggarwal (Moderator)



Prof.Dr. Filippo de Marinis

Director of the Division of Thoracic Oncology, At The European Institute of Oncology, Milan, Italy

On 23 January 2016 | From 7.30 pm At Hotel Shangrila, New Delhi. **Affiliation :** Prof. Dr. Filippo De Marinis is the Director of the Division of Thoracic Oncology at the European Institute of Oncology, Milan, Italy. He is a Professor of Oncology at the Sapienza University of Rome, Italy and is also the Director of the Oncological Pulmonary Unit at the Hospital San Camillo-Forlanini, Rome, Italy.

Education : He completed his training in oncology at the Università Cattolica del Sacro Cuore, Italy (1983-1986) and in pneumology from the Sapienza University of Rome, Italy (1978-1971).

Professional History: He was a Professor of Oncology at the Campus Bio-Medico University, Roma, Italy, was an Executive Manager in the Oncological Pulmonary Unit at Carlo Forlanini Hospital, Rome, Italy and was a Professor at Aix-Marseille University, France.

Prof.Dr. Filippo de Marinis

Areas of Interest: His research interest focuses on the following: lung cancer, biological therapies, drug administration schedule, randomized controlled trials, vinblastine, small cell carcinoma, taxoid and antineoplastic antimetabolites.

Organisations : He is a Faculty member of Chest Tumors of the ESMO, and a member of the : ASCO, AlOM, IASLC, Italian Association of Thoracic Oncology (AlOT) and European Thoracic Oncology Platform (ETOP).

Publications: He has published a significant number of scientific papers, and articles on the following:non-small cell lung carcinoma, lung neoplasms, deoxycytidine, neoplasm staging, antineoplastic agents, carboplatin, paclitaxel and antineoplastic combined chemotherapy protocols. He is a Scientific Board member of the Journal of Clinical Onclogy: Italian version, and is a Reviewer for the multiple Journals including: Annals of Oncology, Aging Health, Cancer Therapy, Cancer Chemotherapy and Pharmacology, Lung Cancer, International Journal of Biomedical Sciences and Journal of Chinese Clinical Medicine.

Clinical Trials: He is an investigator for a phase II study of Vx001 Vaccine in HLA-A*0201 positive patients with TERT positive stage IV or recurrent stage I-III NSCLC, and is a principal investigator for an open-label phase II trial of Erlotinib and Bevacizumab in patients with advanced non-small cell lung cancer and activating EGFR mutations.

Awards: Prof. Dr. De Marinis has won the Public Announcement Employee Award (1991).